# reload+after+2024-01-20 04:46:54.557332
address1§28159 Avenue Stanford
address2§Suite 220
city§Valencia
state§CA
zip§91355
country§United States
phone§661 367 9170
website§https://www.avitamedical.com
industry§Medical Devices
sector§Healthcare
longBusinessSummary§AVITA Medical, Inc. operates as a regenerative medicine company in the United States, Australia, Japan, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's skin. Its lead product is RECELL System, a platform technology allows for the preparation and delivery of spray-on skin cells  to regenerate natural healthy epidermis, as well as to use in the treatment of acute thermal burns in patients eighteen years and older. AVITA Medical, Inc. has a research agreement with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
fullTimeEmployees§126
companyOfficers§[{'maxAge': 1, 'name': 'Mr. James M. Corbett', 'age': 65, 'title': 'CEO, President & Executive Director', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 787103, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Donna  Shiroma', 'age': 61, 'title': 'General Counsel & Secretary', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 642719, 'exercisedValue': 0, 'unexercisedValue': 82949}, {'maxAge': 1, 'name': "Mr. David  O'Toole", 'title': 'Chief Financial Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David  Fencil', 'title': 'Senior Vice President of Global Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jessica  Ekeberg', 'title': 'Investor Relations Executive', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Debbie  Garner', 'title': 'Senior Vice President of Global Marketing & Strategy', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Rob  Hall', 'title': 'Senior Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Terry  Bromley', 'title': 'Senior Vice President of Global Sales', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Niraj  Doshi J.D., P.M.P., Ph.D.', 'title': 'Senior Vice President of Product Development & Program Management', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ron  Lagerquist', 'title': 'Senior Vice President of Quality Assurance & Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§2
compensationRisk§9
shareHolderRightsRisk§5
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.601
priceToSalesTrailing12Months§7.068185
currency§USD
dateShortInterest§1702598400
forwardEps§-1.19
pegRatio§-0.08
exchange§NCM
quoteType§EQUITY
shortName§Avita Medical, Inc.
longName§AVITA Medical, Inc.
firstTradeDateEpochUtc§1337002200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§d9903933-9ef4-3f6b-9dc7-9265028fa3a5
gmtOffSetMilliseconds§-18000000
targetHighPrice§40.0
targetLowPrice§19.0
targetMeanPrice§24.5
targetMedianPrice§21.5
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§5.741
grossMargins§0.83852994
ebitdaMargins§-0.78471
trailingPegRatio§None
